Summary:
Novo Nordisk is launching Ozempic (semaglutide), a groundbreaking weekly injectable weight-loss and diabetes medication, in India, marking a significant innovation in chronic disease treatment.pharma.economictimes.indiatimes

Background:
Ozempic was originally approved by the US FDA in 2017 for managing type 2 diabetes but has since gained global popularity for its notable effects on obesity and weight management. Novo Nordisk’s introduction of Wegovy in India earlier this year positioned it in direct competition with Eli Lilly’s Mounjaro. India has a large burden of diabetes (101 million cases) and obesity (254 million individuals), creating high demand for advanced therapies.pharma.economictimes.indiatimes

Legal/Court Analysis:
Ozempic’s entry follows official regulatory clearance by Indian authorities, demonstrating compliance with India’s drug approval regime overseen by entities like CDSCO. The looming expiry of the semaglutide patent in March 2026 is expected to trigger the launch of generics by Indian pharmaceutical giants, invoking patent law and regulatory provisions for early generic entry. The company recognizes patent expiry as a normal life cycle stage, and the transition is likely to prompt scrutiny of regulatory and IP strategies, especially for market competitiveness and continued patient access.pharma.economictimes.indiatimes

Conclusion:
Ozempic’s launch represents a landmark for patient access and pharma innovation, with intensifying competition, regulatory dynamics, and potential generic entry poised to shape the Indian chronic disease market in the coming year.pharma.economictimes.indiatimes